BIOTECHNOLOGY VALUE FUND L P 4
4 · Olema Pharmaceuticals, Inc. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Olema (OLMA) BVF Partners L.P. Receives 29,500-Share Award
What Happened
BVF Partners L.P. (part of a group of BVF entities reporting jointly) was reported as the recipient of a grant/award of 29,500 derivative shares in Olema Pharmaceuticals (OLMA) on June 18, 2026. The filing records the acquisition as an award (code A) at $0.00 per share (reported value $0). The Form 4 was filed on June 23, 2026.
Key Details
- Transaction date: 2026-06-18 — Award/Grant of 29,500 derivative shares at $0.00 (Acquired).
- Filing date: 2026-06-23 (Form 4 accession 0000921895-26-001653).
- Shares owned after transaction: Not specified in the provided summary of the filing.
- Vesting/terms: Footnote F9 indicates these shares (or related option) vest in 12 equal monthly installments beginning June 18, 2026, subject to continuous service; they vest in full by the next annual meeting if not otherwise fully vested.
- Reporting structure & disclaimers: The Form 4 is filed jointly by multiple BVF entities and Mark N. Lampert (F1–F5). They state membership in a Section 13(d) group and disclaim beneficial ownership except to the extent of pecuniary interest. Footnote F7 notes Gorjan Hrustanovic (an Olema director and member of Partners) has agreed to transfer any economic benefit from these securities to Partners, which is why the BVF group reports this award.
Context
- This was an award/derivative grant (not an open-market purchase or sale). That means it’s an acquisition of derivative rights (likely stock options or RSUs per the vesting language), not an immediate cash investment or liquidation.
- Because the filing is by an institutional group with disclaimers and an arrangement with a director to transfer economic benefit, the report indicates institutional/affiliate economic interest rather than direct personal trading by a single executive.
- No inference about future stock performance should be made solely from this award; it reflects compensation/arrangement terms and potential future ownership as vesting and any exercise occur.
Insider Transaction Report
Form 4
BVF PARTNERS L P/IL
DirectorOther
Transactions
- Award
Stock Option (Right to buy)
[F1][F7][F9]2026-06-18+29,500→ 29,500 total(indirect: See footnote)Exercise: $9.51Exp: 2036-06-18→ Common stock, $0.0001 par value (29,500 underlying)
Holdings
- 2,655,977
Common stock, $0.0001 par value
[F1][F2] - 2,003,966
Common stock, $0.0001 par value
[F1][F3] - 347,970
Common stock, $0.0001 par value
[F1][F4] - 99,556(indirect: See footnote)
Common stock, $0.0001 par value
[F1][F5] - 3,291,004
Pre-Funded Warrant
[F1][F6][F2]Exercise: $0.00→ Common stock, $0.0001 par value (3,291,004 underlying) - 2,627,590
Pre-Funded Warrant
[F1][F6][F3]Exercise: $0.00→ Common stock, $0.0001 par value (2,627,590 underlying) - 336,288
Pre-Funded Warrant
[F1][F6][F4]Exercise: $0.00→ Common stock, $0.0001 par value (336,288 underlying) - 24,150(indirect: See footnote)
Stock Option (Right to buy)
[F1][F7][F8]Exercise: $4.08Exp: 2035-06-11→ Common stock, $0.0001 par value (24,150 underlying) - 23,000(indirect: See footnote)
Stock Option (Right to buy)
[F1][F7][F8]Exercise: $12.36Exp: 2034-06-14→ Common stock, $0.0001 par value (23,000 underlying) - 21,520(indirect: See footnote)
Stock Option (Right to buy)
[F1][F7][F8]Exercise: $7.84Exp: 2033-06-15→ Common stock, $0.0001 par value (21,520 underlying) - 21,520(indirect: See footnote)
Stock Option (Right to buy)
[F1][F7][F8]Exercise: $3.61Exp: 2032-06-16→ Common stock, $0.0001 par value (21,520 underlying) - 21,520(indirect: See footnote)
Stock Option (Right to buy)
[F1][F7][F8]Exercise: $27.66Exp: 2031-06-08→ Common stock, $0.0001 par value (21,520 underlying) - 21,520(indirect: See footnote)
Stock Option (Right to buy)
[F1][F7][F8]Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying) - 21,520(indirect: See footnote)
Stock Option (Right to buy)
[F1][F7][F8]Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying) - 21,520(indirect: See footnote)
Stock Option (Right to buy)
[F1][F7][F8]Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Footnotes (9)
- [F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F2]Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- [F3]Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- [F4]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- [F5]Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.
- [F6]Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise.
- [F7]Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- [F8]The shares subject to the option have fully vested.
- [F9]The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date.